Justin L Mott

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB
    Justin L Mott
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Cell Biochem 110:1155-64. 2010
  2. pmc MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia
    Justin L Mott
    Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 50:630-7. 2009
  3. pmc Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis
    Yuko Akazawa
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Hepatol 52:586-93. 2010
  4. pmc CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis
    Sophie C Cazanave
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Physiol Gastrointest Liver Physiol 299:G236-43. 2010
  5. pmc Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse
    Alisan Kahraman
    Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dig Dis Sci 54:1908-17. 2009
  6. pmc A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA
    Sophie C Cazanave
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN, USA
    J Lipid Res 52:1517-25. 2011
  7. pmc Hedgehog inhibition promotes a switch from Type II to Type I cell death receptor signaling in cancer cells
    Satoshi Kurita
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 6:e18330. 2011
  8. pmc Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis
    Keisuke Kakisaka
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Physiol Gastrointest Liver Physiol 302:G77-84. 2012
  9. pmc JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis
    Sophie C Cazanave
    Miles and Shirley Fitterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 284:26591-602. 2009
  10. pmc Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells
    Christian D Fingas
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 54:2076-88. 2011

Collaborators

Detail Information

Publications25

  1. pmc Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB
    Justin L Mott
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Cell Biochem 110:1155-64. 2010
    ..Thus, in addition to c-Myc, mir-29 expression can be suppressed by hedgehog signaling and inflammatory pathways, both commonly activated in the genesis of human malignancies...
  2. pmc MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia
    Justin L Mott
    Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 50:630-7. 2009
    ..This review will focus on the expression and function of cancer-related microRNAs, including their intimate involvement in tumor suppressor and oncogene signaling networks relevant to hepatobiliary neoplasia...
  3. pmc Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis
    Yuko Akazawa
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Hepatol 52:586-93. 2010
    ..The mono-unsaturated free fatty acid palmitoleate is an adipose-derived lipokine which suppresses free fatty acid-mediated lipotoxicity by unclear mechanisms. Herein we examined the mechanisms responsible for cytoprotection...
  4. pmc CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis
    Sophie C Cazanave
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Physiol Gastrointest Liver Physiol 299:G236-43. 2010
    ..Finally, loss of function studies suggest that both transcription factors are necessary for maximal PUMA induction. Collectively, these data suggest that CHOP and AP-1 cooperatively mediate PUMA induction during hepatocyte lipoapoptosis...
  5. pmc Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse
    Alisan Kahraman
    Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dig Dis Sci 54:1908-17. 2009
    ..In conclusion, increased Mcl-1 expression plays a role in hepatoprotection upon cholestatic liver injury...
  6. pmc A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA
    Sophie C Cazanave
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN, USA
    J Lipid Res 52:1517-25. 2011
    ..We speculate that enhancement of miR-296-5p expression may represent a novel approach to minimize apoptotic damage in human fatty liver diseases...
  7. pmc Hedgehog inhibition promotes a switch from Type II to Type I cell death receptor signaling in cancer cells
    Satoshi Kurita
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 6:e18330. 2011
    ..In conclusion, these data provide additional mechanisms modulating cell death by TRAIL and suggest Hedgehog inhibition as a therapeutic approach for TRAIL-resistant neoplasms...
  8. pmc Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis
    Keisuke Kakisaka
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Physiol Gastrointest Liver Physiol 302:G77-84. 2012
    ..We concluded that LPC-induced lipoapoptosis is dependent on mechanisms largely indistinguishable from PA. These data suggest that FFA-mediated cytotoxicity is indirect via the generation of the toxic metabolite, LPC...
  9. pmc JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis
    Sophie C Cazanave
    Miles and Shirley Fitterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 284:26591-602. 2009
    ..Collectively, the data implicate JNK1-dependent PUMA expression as a mechanism contributing to hepatocyte lipoapoptosis...
  10. pmc Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells
    Christian D Fingas
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 54:2076-88. 2011
    ..Finally, in a rodent CCA in vivo model, cyclopamine administration increased apoptosis in CCA cells, resulting in tumor suppression...
  11. pmc Death receptor 5 signaling promotes hepatocyte lipoapoptosis
    Sophie C Cazanave
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 286:39336-48. 2011
    ..Collectively, these results suggest that ER stress-induced CHOP activation by palmitate transcriptionally up-regulates DR5, likely resulting in ligand-independent cytotoxic signaling by this death receptor...
  12. pmc miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma
    Nataliya Razumilava
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Hepatology 55:465-75. 2012
    ..Computational analysis identified the TRAIL Death Receptor-4 (DR4) as a potential novel miR-25 target, and this prediction was confirmed by immunoblot, cell staining, and reporter assays...
  13. ncbi Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1
    Shogo Kobayashi
    Division of Gastroenterology and Hepatology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Biol Chem 282:18407-17. 2007
    ....
  14. pmc Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines
    Yuko Akazawa
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 136:2365-2376.e1-7. 2009
    ..Our aims were to determine which TRAIL receptor, death receptor (DR) 4 or DR5, mediates lysosomal permeabilization and assess whether receptor endocytosis followed by trafficking to lysosomes contributes in this process...
  15. pmc BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis
    Justin L Mott
    Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
    Mol Cancer Ther 7:2339-47. 2008
    ..In conclusion, obatoclax releases Bak and Bim from Mcl-1 and sensitizes human cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Obatoclax is a potentially promising adjunctive agent for the treatment of this cancer...
  16. pmc Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition
    Ivette M Sosa Seda
    Divisions of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Hepatol Res 40:701-10. 2010
    ..Conclusions: Noxa contributes to proteasome inhibitor-induced apoptosis of stellate cells likely by binding A1. Strategies to therapeutically increase Noxa expression may be useful for inducing HSC apoptosis...
  17. pmc TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse
    Alisan Kahraman
    Miles and Shirley Fitterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 47:1317-30. 2008
    ..05). Likewise, liver histology, number of bile infarcts, serum ALT values, hepatic fibrosis, and animal survival were also improved in BDL TRAIL(-/-) animals as compared to wt animals...
  18. pmc Apoptosis and necrosis in the liver
    Maria Eugenia Guicciardi
    1Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Compr Physiol 3:977-1010. 2013
    ..Because apoptosis is a key feature of so many diseases of the liver, therapeutic modulation of liver cell death holds promise. An updated overview of these concepts is given in this article...
  19. ncbi Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death
    Justin L Mott
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 46:906-11. 2007
  20. pmc Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
    Maria Eugenia Guicciardi
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
    Exp Cell Res 317:107-16. 2011
    ..Targeted depletion of cIAP-1 by SMAC mimetics in conjunction with TRAIL may be beneficial for the treatment of human hepatobiliary malignancies...
  21. pmc Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing
    Hajime Isomoto
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 132:384-96. 2007
    ..Because suppressor of cytokine signaling 3 (SOCS) controls the IL-6/STAT-3 signaling pathway by a classic feedback loop, the aims of this study were to examine SOCS-3 regulation in human cholangiocarcinoma...
  22. pmc Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse
    Alisan Kahraman
    Miles and Shirley Fitterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Hepatol Res 39:805-13. 2009
    ..05). Conclusion: The BDL mouse, liver injury and hepatic fibrosis are attenuated by treatment with the MMP inhibitor CTS-1027. This drug warrants further evaluation as an anti-fibrogenic drug in hepatic injury...
  23. pmc Mmu-miR-615-3p regulates lipoapoptosis by inhibiting C/EBP homologous protein
    Yasuhiro Miyamoto
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 9:e109637. 2014
    ..We speculate that enhancement of miR-615-3p levels may be of therapeutic benefit by inhibiting palmitate-induced hepatocyte lipoapoptosis. ..
  24. ncbi Predisposed to toxins: association of gallbladder cancer with N-acetyl transferase SNPs
    Justin L Mott
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Biol Ther 6:97-8. 2007
  25. ncbi Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse
    Akira Anan
    Mayo Clinic College of Medicine, 200 First St SW, Rochester, Minnesota 55905, USA
    Am J Physiol Gastrointest Liver Physiol 291:G709-16. 2006
    ....